Abstract:Immune checkpoint inhibitors (ICIs) have dramatically changed the way we treat advanced non-small cell lung cancer (NSCLC). Compared to chemotherapy alone, ICIs significantly improve overall survival, and these survival benefits are durable. Unfortunately, only a minority of patients benefit from ICI therapy. Most advanced NSCLC patients are non-responders. Several factors may contribute to poor response rates. One, we may not be correctly identifying the patients who could benefit from ICIs. Currently, PD-L1 is the only predictive biomarker; yet not all tumors that express PD-L1 are responsive. Two, blocking checkpoints to restore cytotoxic T lymphocyte (CTL) function may be insufficient to cure disease. The tumor microenvironment (TME) likely remains hostile to CTLs even after ICI therapy. The TME may continue inhibiting infiltrated CTLs or may prevent CTL infiltration in the first place. To effectively re- invigorate CTL-mediated anti-tumor responses, we must remodel the TME into one that is hospitable for CTLs; however, our understanding of the TME is limited. Here, we demonstrate the use of spatial transcriptomics to (1) identify novel predictive biomarkers for ICI therapy, and (2) generate a comprehensive profile of the NSCLC TME. Using Nanostring's GeoMX Digital Spatial Profiler (DSP), we performed spatial analysis on 56 human NSCLC tumors. Using the DSP's state-of-the-art UV masking technology, we generated transcriptomic profiles of CD8+ CTLs, the vimentin+ stroma, and the vimentin- tumor. We grouped the profiles of each compartment using their inflammatory status—hot/inflamed, or cold/not-inflamed—to identify differentially expressed genes that correspond to the immune phenotype of the tumors. We identified 112 DEGs in CD8+T cells and found that T cells in cold tumors were functional but poorly migratory. Strikingly, T cells in hot tumors were dysfunctional but motile and able to infiltrate tumors. 41 DEGs were identified in the Vimentin+ stroma. The stroma of hot tumors was enriched in CEACAM1, HMGB1, and LGALS9—all ligands of TIM3, a known immune checkpoint. The stroma of cold tumors expressed higher levels of JAG2, LTB4R, and SEMA4C. Bioinformatic analysis of TCGA data indicated that all three molecules are negatively correlated with CD8A levels in NSCLC tumors, which suggests that these molecules could promote T cell exclusion. 29 DEGs were identified in the tumor, and hot tumors were enriched in pathways associated with cellular migration and inhibition of immune effectors. In depth analysis of molecules upregulated in cold T cells revealed five new potential predictive biomarkers. CD2, CD52, KLRK1, NKG7, and PTPRC are upregulated in responders, and higher expression of these molecules corresponded to improved response to anti-PD1 therapy. In sum, our innovative studies highlight the utility of spatial transcriptomics in profiling the TME and identify new biomarkers that could be used to predict response to ICI therapy. Citation Format: Christina Cho, Francesc Lopez, Gavitt Woodard, Baozhu Huang, Jianwei He, Tayf Badri, Michal Kidacki, Matthew Vesely, Evelyn Ng, Guilin Wang, Lieping Chen. Spatial transcriptomics to profile the non-small cell lung cancer tumor microenvironment and identify novel predictive biomarkers for checkpoint blockade [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2024 Oct 18-21; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2024;12(10 Suppl) nr PR-08.

Immune Cell Densities Predict Response to Immune Checkpoint-Blockade in Head and Neck Cancer

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy

A Novel Immune Signature Predicts Immunotherapy Responsiveness and Reveals the Landscape of the Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma

B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma

Correlation of Specific Genetic Aberrations and Signaling Pathways with T-cell Inflamed Phenotype (TCIP) in Head and Neck Cancer and As Novel Candidate Biomarkers for Checkpoint Blockade Therapy.

Diagnostic Predictors of Immunotherapy Response in Head and Neck Squamous Cell Carcinoma

Spatial predictors of immunotherapy response in triple-negative breast cancer

Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma

A Combination of Biomarkers Predict Response to Immune Checkpoint Blockade Therapy in Non-Small Cell Lung Cancer

Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma

Intratumoral Tertiary Lymphoid Structures Promote Patient Survival and Immunotherapy Response in Head Neck Squamous Cell Carcinoma

Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma

Abstract PR-08: Spatial transcriptomics to profile the non-small cell lung cancer tumor microenvironment and identify novel predictive biomarkers for checkpoint blockade

Abstract 1154: Spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma revealed immune cell type infiltration into the TME as a predictor of immunotherapy response

Immune Infiltration Characteristics and a Gene Prognostic Signature Associated With the Immune Infiltration in Head and Neck Squamous Cell Carcinoma

Abstract 4488: Effector B cells and tertiary lymphoid structures predict response to immune checkpoint blockade in solid tumors

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma

Spatial mapping reveals unique cellular interactions and enhanced tertiary lymphoid structures in responders to anti-PD-1 therapy in mucosal head and neck cancers

Treatment response of advanced HNSCC towards immune checkpoint inhibition is associated with an activated effector memory T cell phenotype

CXCL13 Positive Cells Localization Predict Response to Anti-PD-1/PD-L1 in Pulmonary Non-Small Cell Carcinoma